Breadcrumb

What's New at the RI-MUHC ?

Saliva samples for COVID-19 testing: as good as nasopharyngeal swabs, but cheaper

New meta-analysis of 37 studies and over 7,000 paired saliva and nasopharyngeal swab samples

Could an antidepressant slow COVID-19 progression?

RI-MUHC researchers launch a clinical trial of fluvoxamine, a drug that has already proven efficient in reducing lung injury in animal studies and...

Clinical Innovation Platform at the RI-MUHC announces first member company

Health tech accelerator welcomes AltPAP Innovation to its new state-of-the-art facility

Haply wins the CODE LiFE Ventilator Challenge

What’s next? “Gather the resources to bring the Haply device to millions around the world,” says Reza Farivar

Researchers identify the origin of a deadly brain cancer

Finding could lead to potential therapies

The RI-MUHC leads new clinical trial of COVID-19 treatment for hospitalized patients

Phase 2 study tests LAU-7b, a Canadian drug with dual antiviral and inflammation-controlling effects

RI-MUHC veterinarians engage in global effort to understand SARS-Cov-2

ARD platform members take centre stage at the 2020 Quebec Veterinary Congress

RI-MUHC researcher Nitika Pant Pai advocates improved access to HIV self-testing for Canadians

Canada approves HIV self-testing kit ahead of World AIDS Day 2020

Learn more about the RI-MUHC